117 related articles for article (PubMed ID: 25431474)
1. Risk of RAS in relapsed childhood ALL.
Paulsson K
Blood; 2014 Nov; 124(23):3338-9. PubMed ID: 25431474
[No Abstract] [Full Text] [Related]
2. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.
Irving J; Matheson E; Minto L; Blair H; Case M; Halsey C; Swidenbank I; Ponthan F; Kirschner-Schwabe R; Groeneveld-Krentz S; Hof J; Allan J; Harrison C; Vormoor J; von Stackelberg A; Eckert C
Blood; 2014 Nov; 124(23):3420-30. PubMed ID: 25253770
[TBL] [Abstract][Full Text] [Related]
3. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia.
Oshima K; Khiabanian H; da Silva-Almeida AC; Tzoneva G; Abate F; Ambesi-Impiombato A; Sanchez-Martin M; Carpenter Z; Penson A; Perez-Garcia A; Eckert C; Nicolas C; Balbin M; Sulis ML; Kato M; Koh K; Paganin M; Basso G; Gastier-Foster JM; Devidas M; Loh ML; Kirschner-Schwabe R; Palomero T; Rabadan R; Ferrando AA
Proc Natl Acad Sci U S A; 2016 Oct; 113(40):11306-11311. PubMed ID: 27655895
[TBL] [Abstract][Full Text] [Related]
4. Advances in the management of Ph-positive ALL.
Hoelzer D
Clin Adv Hematol Oncol; 2006 Nov; 4(11):804-5. PubMed ID: 17143248
[No Abstract] [Full Text] [Related]
5. Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance.
Ariës IM; van den Dungen RE; Koudijs MJ; Cuppen E; Voest E; Molenaar JJ; Caron HN; Pieters R; den Boer ML
Haematologica; 2015 Apr; 100(4):e132-6. PubMed ID: 25480501
[No Abstract] [Full Text] [Related]
6. BCR/ABL1 Kinase Domain Mutation Monitoring: Could Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Benefit As Well?
Andolina JR
Acta Haematol; 2015; 134(2):69-70. PubMed ID: 25895547
[No Abstract] [Full Text] [Related]
7. Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia.
Lu SX; Abdel-Wahab O
Proc Natl Acad Sci U S A; 2016 Oct; 113(40):11071-11073. PubMed ID: 27663730
[No Abstract] [Full Text] [Related]
8. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.
Soverini S; De Benedittis C; Papayannidis C; Polakova KM; Venturi C; Russo D; Bresciani P; Iurlo A; Mancini M; Vitale A; Chiaretti S; Foà R; Abruzzese E; Sorà F; Kohlmann A; Haferlach T; Baccarani M; Cavo M; Martinelli G
Leukemia; 2016 Jul; 30(7):1615-9. PubMed ID: 26867670
[No Abstract] [Full Text] [Related]
10. Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia.
Hanif A; Wang ES; Thompson JE; Baron JI; Walsh MD; Griffiths EA
Leuk Lymphoma; 2018 Aug; 59(8):2011-2013. PubMed ID: 29251203
[No Abstract] [Full Text] [Related]
11. Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Fielding AK
Hematology Am Soc Hematol Educ Program; 2011; 2011():231-7. PubMed ID: 22160039
[TBL] [Abstract][Full Text] [Related]
12. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
Pfeifer H; Lange T; Wystub S; Wassmann B; Maier J; Binckebanck A; Giagounidis A; Stelljes M; Schmalzing M; Dührsen U; Wunderle L; Serve H; Brück P; Schmidt A; Hoelzer D; Ottmann OG
Leukemia; 2012 Jul; 26(7):1475-81. PubMed ID: 22230800
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
[TBL] [Abstract][Full Text] [Related]
15. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
[TBL] [Abstract][Full Text] [Related]
16. Beating the Clock in T-cell Acute Lymphoblastic Leukemia.
Carroll WL; Aifantis I; Raetz E
Clin Cancer Res; 2017 Feb; 23(4):873-875. PubMed ID: 28007775
[TBL] [Abstract][Full Text] [Related]
17. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G
Haematologica; 2007 Mar; 92(3):401-4. PubMed ID: 17339191
[TBL] [Abstract][Full Text] [Related]
18. Thiopurine Resistance in Childhood ALL Is Mediated by PRPS1 Mutations.
Cancer Discov; 2015 Jul; 5(7):693. PubMed ID: 25998402
[TBL] [Abstract][Full Text] [Related]
19. Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Swords R; Alvarado Y; Giles F
Clin Lymphoma Myeloma; 2007 Mar; 7 Suppl 3():S113-9. PubMed ID: 17382020
[TBL] [Abstract][Full Text] [Related]
20. Childhood leukemia--new advances and challenges.
Winick NJ; Carroll WL; Hunger SP
N Engl J Med; 2004 Aug; 351(6):601-3. PubMed ID: 15295054
[No Abstract] [Full Text] [Related]
[Next] [New Search]
